Global Psoriatic Arthritis Treatment Market to Reach USD 23.2 Billion by 2033, Impelled by Rising Prevalence of Autoimmune Illnesses

December 18, 2024 | Healthcare

According to the latest report by IMARC Group, titled "Psoriatic Arthritis Treatment Market Report by Drug Type (NSAIDs (Nonsteroidal Anti-Inflammatory drugs), DMARDs (Disease-Modifying Anti-Rheumatic Drugs), Biologics, and Others), Type (Prescription, OTC), Route of Administration (Injectable, Oral, Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2025-2033," the global psoriatic arthritis treatment market reached a value of USD 10.5 Billion in 2024. Psoriatic arthritis is a form of a disease that affects any part of the body, causing stiffness, joint pain and swelling. It is generally prevalent in patients suffering from plaque psoriasis that develops patches of red, flaky skin with silvery and white scales. Its treatment is commonly available in the form of oral medications as well as biological therapies that aid in controlling symptoms and preventing joint damage. Due to the increasing awareness among the masses regarding the adverse effects of the chronic degenerative condition, there has been a considerable rise in the adoption of psoriatic arthritis treatment.


Global Psoriatic Arthritis Treatment Market Trends:

The global market is primarily driven by the growing prevalence of autoimmune illnesses among the masses. This is supported by the increasing occurrence of infections and skin injuries, coupled with the rising population leading sedentary lifestyles resulting in obesity and stress. Along with this, multiple initiatives undertaken by private and public organizations, such as conducting campaigning and medical programs, in order to create awareness among individuals are catalyzing the demand for psoriatic arthritis treatment across the globe. Moreover, the growing investments by leading players for conducting extensive research and development (R&D) activities to introduce improved treatment options are creating a positive market outlook. Additionally, continual technological advancements and the emergence of biosimilars and biological therapies are impacting the market growth favorably. Other factors, including the increasing geriatric population, growing patient pool, continual improvements in the healthcare infrastructure and the development of medical facilities across rural and geographical extended locations, are also positively influencing the market. Looking forward, the market value is projected to reach USD 23.2 Billion by 2033, expanding at a CAGR of 8.71% during 2025-2033


Market Summary:

  • On the basis of drug type, the market has been segmented into NSAIDs (nonsteroidal anti-inflammatory drugs), DMARDs (disease-modifying anti-rheumatic drugs), biologics and others.
  • Based on the type, the market has been segregated into prescription and OTC.
  • On the basis of the route of administration, the market has been categorized into injectable, oral and topical.
  • Based on the distribution channel, the market has been classified into hospital, retail and online pharmacies.
  • On the basis of the region, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil, Mexico and others) and the Middle East and Africa.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of the key players are AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca plc, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Johnson & Johnson Service ltd., Novartis AG, Pfizer Inc., Samsung Biologics and UCB S.A.

Report Scope:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units  Billion USD
Segment Coverage Drug Type, Type, Route of Administration, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca plc, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Johnson & Johnson Service ltd., Novartis AG, Pfizer Inc., Samsung Biologics and UCB S.A.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Psoriatic Arthritis Treatment Market to Reach USD 23.2 Billion by 2033, Impelled by Rising Prevalence of Autoimmune Illnesses
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials